Latest Leadership Changes News

Murray Cod Australia has appointed Steven Chaur as its new Managing Director and CEO, aiming to accelerate revenue growth and operational efficiency from April 2026. The move signals a strategic push to deepen domestic channels and expand the luxury fish brand’s market presence.

Li-S Energy narrows its loss to $1.21 million in H1 2026, propelled by a $7.8 million ARENA grant and key manufacturing milestones including Australia’s first lithium metal foil production line. Strategic defence and aerospace partnerships bolster its commercialisation drive.

Peter Warren Automotive Holdings reported a 3.2% revenue increase to $1.268 billion and more than doubled its profit after tax to $7.435 million in the first half of FY26, declaring a fully franked interim dividend of 3.0 cents per share.

Terragen Holdings reports a 23% reduction in half-year net loss amid strategic shifts and completes a $7 million equity raise to accelerate global commercialisation of its biological agricultural products.

Motio Limited has reported its first-ever net profit alongside a 39% surge in cash EBITDA, underpinned by strategic cost discipline and a strengthened balance sheet. The company is now poised to accelerate network growth, particularly in the health sector.

Adrad Holdings reported a modest revenue rise and a dip in statutory profit for the half-year ending December 2025, while its Heat Transfer Solutions segment showed robust growth. The company declared a fully franked interim dividend, reflecting confidence amid ongoing restructuring.

Enero Group’s half-year results reveal a 6.3% revenue decline but a striking 119% surge in adjusted profit, alongside strategic leadership changes and a steady dividend.

IPH Limited reported a solid half-year performance with revenue up 6.5% to $363.9 million and net profit rising 10.5% to $41.2 million, driven by strong gains in Canada and Asia despite a decline in Australia and New Zealand.

Ventia Services Group Limited reported a 23.6% increase in profit after tax for FY25 to $272.2 million, alongside record contract wins and a strong sustainability agenda. The company declared a 12.54 cents per share final dividend, underscoring its commitment to shareholder returns and operational excellence.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

IDT Australia reports a robust 20.3% increase in core revenue and a dramatic narrowing of EBITDA losses, signalling early success from its strategic realignment under new leadership.

INOVIQ Limited reported a $3.96 million net loss for H1 2026, driven by increased R&D spend, while securing $10.2 million to accelerate its exosome-based cancer diagnostics and therapeutics pipeline.